0.05Open0.05Pre Close0 Volume30 Open Interest72.00Strike Price0.00Turnover164.28%IV7.87%PremiumNov 29, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0350Delta0.0218Gamma1562.00Leverage Ratio-0.4621Theta0.0000Rho-54.66Eff Leverage0.0017Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet